Insulin Secretion (Oral Glucose Tolerance Test Sample Clauses

Insulin Secretion (Oral Glucose Tolerance Test. Cystic fibrosis related diabetes (CFRD) is characterized by progressive insulin insufficiency. It is extraordinarily prevalent in the CF population, occurring in 15-20% of adolescents and, eventually, more than half of adults.59 Few of the remaining patients have completely normal glucose metabolism; even those with normal fasting and 2-hour OGTT glucose levels typically have mid-OGTT glucose elevation (indeterminate glycemia) and have defective acute insulin secretion in response to intravenous glucose.60 While CFRD does not usually develop before puberty, it has its roots in childhood and glucose intolerance is common in 6-9 year old children with CF.61 In childhood, CF patients are able to compensate for this defect because their beta-cell mass is largely intact. As islets are lost over time due to exocrine fibrosis and as chronic, unrelenting beta-cell stress occurs due to inflammation, oxidative stress and recurrent infection, the impact of CFTR on insulin secretion becomes more critical. We postulate that CFTR plays a small but important role in insulin secretion. A pilot study in five CF patients with the G551D CFTR mutation that measured insulin secretion before and 1 month after initiation of ivacaftor therapy provided preliminary evidence that drugs that improve CFTR function may increase insulin secretion in CF. After 1 month of ivacaftor therapy, the insulin response to oral glucose improved by 66-178% in all subjects except the one with long standing diabetes (p=0.07). While childhood may be the ideal time to intervene (with the hope of establishing a healthy “bank” of fully functional beta cells which are better able to withstand the metabolic stresses of CF that escalate over time) further data needs to be gathered in adults before studying children. Longitudinal assessment of a greater number of subjects with CF is necessary to determine whether early correction of CFTR could delay or even prevent diabetes. Oral glucose tolerance testing will be performed in a subset of subjects enrolled in the Part B CORE study to examine the role of CFTR in human insulin secretion, potentially opening the way for novel diabetes therapies and for prevention or at least amelioration of diabetes in CF.
Sample 1
AutoNDA by SimpleDocs

Related to Insulin Secretion (Oral Glucose Tolerance Test

  • Substance Abuse Testing The Parties agree that it is in the best interest of all concerned to promote a safe working environment. The Union has no objection to pre-employment substance abuse testing when required by the Employer and further, the Union has no objection to voluntary substance abuse testing to qualify for employment on projects when required by a project owner. The cost and scheduling of such testing shall be paid for and arranged by the Employer. The Union agrees to reimburse the Employer for any failed pre-access Alcohol and Drug test costs.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Stability Testing Patheon may be requested to conduct stability testing on the Products in accordance with the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C to a Product Agreement. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will bear the cost of the investigation. Patheon will not be liable for these costs unless it has failed to perform the Manufacturing Services in accordance with the Specifications, cGMPs, and Applicable Laws. Patheon will give Client ail stability test data and results at Client’s request.

  • Random Testing Notwithstanding any provisions of the Collective Agreement or any special agreements appended thereto, section 4.6 of the Canadian Model will not be applied by agreement. If applied to a worker dispatched by the Union, it will be applied or deemed to be applied unilaterally by the Employer. The Union retains the right to grieve the legality of any imposition of random testing in accordance with the Grievance Procedure set out in this Collective Agreement.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Drug Testing (A) The state and the PBA agree to drug testing of employees in accordance with section 112.0455, F.S., the Drug-Free Workplace Act. (B) All classes covered by this Agreement are designated special risk classes for drug testing purposes. Special risk means employees who are required as a condition of employment to be certified under Chapter 633 or Chapter 943, F.S. (C) An employee shall have the right to grieve any disciplinary action taken under section 112.0455, the Drug-Free Workplace Act, subject to the limitations on the grievability of disciplinary actions in Article 10. If an employee is not disciplined but is denied a demotion, reassignment, or promotion as a result of a positive confirmed drug test, the employee shall have the right to grieve such action in accordance with Article 6.

  • ODUF Testing 6.6.1 Upon request from TWTC, AT&T shall send ODUF test files to TWTC. The Parties agree to review and discuss the ODUF file content and/or format. For testing of usage results, AT&T shall request that TWTC set up a production (live) file. The live test may consist of TWTC’s employees making test calls for the types of services TWTC requests on ODUF. These test calls are logged by TWTC, and the logs are provided to AT&T. These logs will be used to verify the files. Testing will be completed within thirty (30) days from the date on which the initial test file was sent.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Acceptance Testing At the time of installation of a LIS trunk group, and at no additional charge, acceptance tests will be performed to ensure that the service is operational and meets the applicable technical parameters.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!